IL-20 Antagonist Antibody for Spinal Cord Injury Secondary Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neural injuries, such as spinal cord injuries, are inadequate in addressing the secondary injury mechanisms that lead to further neurological deficits and functional loss.
Innovation Solution
Administration of an IL-20 antagonist, specifically an anti-IL-20 antibody that interferes with the IL-20 signaling pathway, to alleviate symptoms and preserve neural functions in subjects with neural injuries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for spinal cord injury are used, then initial trauma effects are addressed, but secondary injury mechanisms are not effectively controlled leading to further neurological deficits
Solution Approach 1:
The patent applies preliminary anti-action by administering an IL-20 antagonist before secondary injury mechanisms can fully develop and cause additional neurological damage. The antagonist blocks the IL-20 signaling pathway proactively, preventing the cascade of harmful cellular events that would otherwise follow spinal cord injury, thereby addressing secondary injury mechanisms before they can fully manifest their harmful effects
Solution Approach 2:
The patent converts the harmful IL-20 signaling pathway into a beneficial target for intervention. By identifying that IL-20 contributes to secondary injury mechanisms, the invention transforms this previously harmful molecular pathway into a specific target that, when blocked by the IL-20 antagonist, produces therapeutic benefit and reduces neurological deficits
2Reliability
If new treatment approaches targeting secondary injury are developed, then neurological function preservation is improved, but treatment complexity increases
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting a specific molecular pathway (IL-20 signaling) that drives secondary injury mechanisms. Rather than attempting to address the entire complex cascade of post-injury events, the invention extracts and blocks the specific IL-20 pathway, simplifying the treatment approach while maintaining effectiveness in preserving neurological function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL-20 antagonist effectively reduces symptoms and improves motor performance by suppressing the IL-20 signaling pathway, as demonstrated in spinal cord injury models, indicating potential for treating various neural injuries.
Implementation Method 1
an antibody that binds to an IL-20 protein (e.g., human IL-20) or an antibody that binds to an IL-20 receptor (e.g., human IL-20 receptor or a subunit of the receptor)
Data Source
AI summary
Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.